Share Name Share Symbol Market Type Share ISIN Share Description
Maxcyte Inc LSE:MXCT London Ordinary Share COM STK USD0.01 (DI)
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 410.00 28,213 07:47:18
Bid Price Offer Price High Price Low Price Open Price
400.00 420.00 410.00 410.00 410.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 16.30 -9.72 -17.34 273
Last Trade Time Trade Type Trade Size Trade Price Currency
16:34:58 O 15,645 410.00 GBX

Maxcyte (MXCT) Latest News

More Maxcyte News
Maxcyte Investors    Maxcyte Takeover Rumours

Maxcyte (MXCT) Discussions and Chat

Maxcyte Forums and Chat

Date Time Title Posts
22/10/202010:06Maxcyte: Any molecule, any cell, any scale268
13/7/201613:43MaxCyte (MXCT) Right here, right now: catching the CAR-T wave2

Add a New Thread

Maxcyte (MXCT) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Maxcyte trades in real-time

Maxcyte (MXCT) Top Chat Posts

Maxcyte Daily Update: Maxcyte Inc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker MXCT. The last closing price for Maxcyte was 410p.
Maxcyte Inc has a 4 week average price of 355p and a 12 week average price of 247p.
The 1 year high share price is 440p while the 1 year low share price is currently 105p.
There are currently 66,684,917 shares in issue and the average daily traded volume is 80,415 shares. The market capitalisation of Maxcyte Inc is £273,408,159.70.
rgmgo: Sad news out on a trial from CRISPR Therapeutics MXCT is clearly insulated from the economic effect of any particular programme due to its diverse royalty pipeline. Further details will presumably emerge on the precise circustances and whether there are any broader implications.
the stigologist: Video explaining Crispr for AIM investors #HZD #MXCT #C4XD htTps://
davegk: Found the answer The Company currently has two lines of Common Stock admitted to trading on AIM: an unrestricted line of Common Stock trading under the symbol MXCT and a new restricted line of Common Stock under the symbol MXCL which is restricted under Regulation S Category 3 such that purchasers cannot sell or otherwise transfer such Common Stock except pursuant to the requirements of Regulation S until at least the expiry of one year after the closing of the offering which closed on 22 May 2020. There are no other restrictions on the transfer of AIM securities.
davegk: Why the two epic's MXCT & MXCL ?
adamb1978: I wouldn't sell for anything close to 500p per share! They're a picks and shovels company and if they can maintain a 20%-30% growth rate from continually increasing their installed base, they could be worth 10x the current share price in 5-10 years' time!!
multibagger: Another strong blue day and MXCT seems to be powering along and share price gathering momentum, disappointing those who were waiting for a pull back to enter.I have been averaging up and have a decent stake now. Still feel that the market does not seem to appreciate the quality and applicability of the MXCT IP and prospects from a scientific perspective. I wonder if any of the specialist biotech/pharma/healthcare funds are building a bigger stake, which could explain some massive trades over the recent period. With so many irons in the fire, a RNS announcing the triggering of a milestone payment will really bring this to the wider market attention. I agree NASDAQ listing will be pretty transformational ! Good luck all :)
davep4: Those who invested in March 2017 have just broken into profit; "Results of Placing Maryland, USA - 12.30 p.m., 31 March 2017: MaxCyte (LSE: MXCT), a US-based global company dedicated to driving the acceleration of the discovery, development, manufacturing and commercialisation of next-generation, cell-based medicines, is pleased to announce the completion of the Placing announced earlier today. A total of 7,275,000 shares of New Common Stock have been placed by Panmure Gordon at a Placing Price of 275 pence per share of New Common Stock to raise a total of approximately GBP20.0 million for the Company (before expenses)."
multibagger: Guessing that H1 v H2 could be related to customer R&D budgets which need to be spent before financial year ? The way MXCT have structured their deals (both clinical and commercial) is hugely profitable from a maximisation of their IP point of view. Though many scientific companies have very strong IP, monetisation of the same is often a challenge. Let's see how the market likes the update, but I won't rule out circa +8p to the share price today !
multibagger: Very interesting presentation this evening with numbers attached demonstrating the robustness of the MXCT business model and exceptional IP they hold and are able to monetise. I won't be surprised if this exceeds BVXP in growth and profitability margins (apart from share price) in the not too distant future and a stock market darling in the making. Many thanks to gsbmba99 for pointing me in the direction of this stock - a very astute investor, gifted researcher and a top notch numbers man !
adamb1978: I'm not sure how but stumbled upon this company a couple days ago and so bought in this morning. Seems far too cheap. Even if you put zero value on the Carma investment and assume that the cash is frittered away without generating any benefit, I'd still argue that the recurring revenue nature of the base business should imply a higher multiple and is worth the share price today. There's many catalysts, including the Nasdaq listing which could push this share price several times higher over the next 3-4 years.
Maxcyte share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201026 23:00:16